Robocath Updates Progress With R-One Robotic Coronary Intervention Platform
Executive Summary
French company Robocath believes its R-One robotic catheter intervention system will make coronary interventions more efficient for hospitals and safer for interventionalists. Robocath is sponsoring a 60-patient European trial of coronary interventions with R-One.
You may also be interested in...
Corindus Sees ‘Silver Lining’ As Pandemic Shows Need For Remote Interventions
The Siemens Healthineers subsidiary is planning to create networks of CorPath GRX robotic intervention systems that will expand patient access to urgent interventions and reduce radiation exposure for both the patient and interventionalists.
Corindus Envisions Network Of CorPath Robots For Remote Neurovascular And Coronary Interventions
The physician who led the first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.
EuroPCR 2018: Robocath Eyes December CE Mark For R-One Positive Pre-Clin Data
Robocath is planning a year-end market launch of its flagship R-One robotic catheterization system after the preclinical trial of R-One hit all primary endpoints. If the product is CE-marked in December as anticipated, it will be a rival to Corindus Vascular's CorPath, which is currently the only robotic-assisted system in the market for interventional cardiology. Robocath announced the preclinical data at EuroPCR in Paris, being held this week until May 25.